AstraZeneca to Acquire Neogene Therapeutics, Accelerating Ambition in Oncology Cell TherapyBusiness Wire • 11/29/22
C4X Discovery Holdings plc: C4XD signs exclusive global licence worth up to $402 million¹ with AstraZeneca for the development and commercialisation of NRF2 Activator programmeGlobeNewsWire • 11/28/22
AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022Business Wire • 11/22/22
Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® TherapeuticsBusiness Wire • 11/16/22
LogicBio Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdatesPRNewsWire • 11/14/22
ENHERTU® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Advanced Gastric CancerBusiness Wire • 11/14/22
AstraZeneca Makes A Break For A Buy Point On Massive Third-Quarter GrowthInvestors Business Daily • 11/10/22
Worried About a Recession? Park Your Money In These 2 High-Yielding Dividend StocksThe Motley Fool • 11/10/22
Options Traders Expect AstraZeneca Shares To Fall After Earnings Report, As Stock Is Up 5% In 2022 - AstraZeneca (NASDAQ:AZN)Benzinga • 11/09/22